secwatch.observer — SEC 8-K summary
======================================

Issuer:     TherapeuticsMD, Inc. (TXMD)
CIK:        0000025743
Form:       8-K
Filed at:   2025-03-27T23:59:59+00:00
Accession:  0001013762-25-003407
Event type: earnings
Sentiment:  positive
Materiality: 0.60
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

TherapeuticsMD reports FY2024 net loss narrowed to $2.3M; license revenue up 35%
--------------------------------------------------------------------------------

- Net loss from continuing operations $(2.3)M, or $(0.20)/share, improved from $(7.7)M loss in 2023.
- License revenue $1.8M, up 35.3% YoY, driven by changes in sales of Mayne licensed products.
- Total operating expenses $6.5M, down 33.6% from $9.8M, due to cost cuts and transition to royalty model.
- Cash and cash equivalents $5.1M as of December 31, 2024.
- Company continues to evaluate strategic alternatives including M&A, sale of assets, or other transactions.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/25743/000101376225003407/0001013762-25-003407-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/25743/000101376225003407/ea0235200-8k_therap.htm
  HTML page:      https://secwatch.observer/filing/0001013762-25-003407

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer